MTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): The question remains open

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 242-244

  Jardine, Meg J ^a,b   Liyanage, Thaminda ^a,c   Buxton, Erin ^a,c   Perkovic, Vlado ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; POLYCYSTIN 1; POLYCYSTIN 2; RAMIPRIL; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ARTICLE; CHINESE MEDICINE; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; GENE MUTATION; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LOW DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PKD1 GENE; PKD2 GENE; PRIORITY JOURNAL; PROTEINURIA; SALT INTAKE; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES, CYSTIC; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIROLIMUS;

EID: 84874516609     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs519     Document Type: Article

References (22)

1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 49
2. Patel V, Chowdhury R, Igarashi P. Advances in the pathogenessis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 99
3. Rossetti S, Consugar MB, Chapman AB et al. Comprehensive molecular diagnostic in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143
4. Hateboer N, van Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999; 353: 103-107 (Pubitemid 29088079)
5. Harris PC, Rossetti S. Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010; 6: 197-206
6. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471
7. Wuthrich RP, Kistler AD, Serra AL. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Transplant Proc 2010; 42 (9 Suppl): S44-S46
8. Torres VE. Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis 2010; 17: 190-204
9. Qian Q, Du H, King BF et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19: 631-638 (Pubitemid 351355407)
10. Grantham JJ, Torres VE, Chapman AB, Jr et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130 (Pubitemid 43736612)
11. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840
12. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829
13. Watnick T, Germino GG. mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010; 363: 879-881
14. Perico N, Remuzzi G. Polycystic kidney disease: do mTOR inhibitors still have a future in ADPKD? Nat Rev Nephrol 2010; 6: 696-698
15. Canaud G, Knebelmann B, Harris PC et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant 2010; 10: 1701-1706
16. Perico N, Antiga L, Caroli A et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031-1040
17. NCT00286156: Pilot study of rapamycin as treatment for autosomal dominant polycystic kidney disease (ADPKD) [database on the Internet]. US National Institutes of Health. [cited 20 June 2012]. Available from: http:// clinicaltrials.gov/ct2/show/NCT00286156.
18. Stallone G, Infante B, Grandaliano G et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYDstudy): a randomized, controlled study. Nephrol Dial Transplant 2012; 27: 3560-3567.
19. Harris PC, Rossetti S. Determinants of renal disease variability in ADPKD. Adv Chronic Kidney Dis 2010; 17: 131-139
20. Chapman AB, Torres VE, Perrone RD et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010; 5: 102-109
21. Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011; 57: 692-699
22. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl JMed 2001; 345: 851-860